drugset
drugset / Trial / NCT03768089

Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis

NCT03768089 ↗

Phase 1/2 Completed 115 enrolled Vertex Pharmaceuticals Incorporated
RandomizedSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate safety and tolerability of VX-121 in healthy subjects and in subjects with cystic fibrosis (CF).

Timeline

Start
2018-03-20
Primary completion
2019-05-03
Completion
2019-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Vanzacaftor Small molecule 5 mg Oral
Subject Vanzacaftor Small molecule 10 mg Oral
Subject Vanzacaftor Small molecule 20 mg Oral
Subject Vanzacaftor Small molecule 40 mg Oral
Subject Vanzacaftor Small molecule 60 mg Oral
Background IVA Unknown 150 mg Oral
Background TEZ/IVA Unknown 100 mg Oral
Background TEZ/IVA Unknown 150 mg Oral

Indications

cystic fibrosis